DRI Healthcare agrees to buy tavapadon royalty rights for US$316 million upon FDA approval

DRI Healthcare Trust agreed to buy U.S. royalty participation rights on Parkinson’s candidate tavapadon for USD 316 million. Closing is contingent on FDA approval, expected in Q3 2026, along with other customary conditions. Deal includes tiered royalties on annual U.S. net sales at mid-single digit to low-double digit rates. Consideration also includes sales milestones, four annual fixed payments of USD 23.4 million, capped at USD 437.5 million total receipts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DRI Healthcare Trust published the original content used to generate this news brief via CNW (Ref. ID: 202609210700CANADANWCANADAPR_C4334) on September 21, 2026, and is solely responsible for the information contained therein. (C)